{
  "id": 15827298,
  "title": "Advancing CD38 from a marker of disease activity to an active regulator of interferon responses in juvenile dermatomyositis",
  "url": "https://urgent.news/2026/10/20/advancing-cd38-from-a-marker-of-disease-activity-to-an-active",
  "topic": "science",
  "section": "Science",
  "published": "2026-10-20T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.10.14.758964v1?rss=1"
  },
  "original_language": "en",
  "account": null,
  "summary": "Juvenile dermatomyositis (JDM), the most common pediatric inflammatory myopathy, is driven by an overactive immune signaling pathway called type I interferon. Current treatment relies on broadly immunosuppressive agents that lack mechanistic specificity, often fail to achieve durable disease control, and can result in off-target toxicity and irreversible disease-related damage in many patients.…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}